Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 6/20 | 0.82 |
| ▸ | TNFSF11 | O14788 | 6/20 | 0.74 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21162208 | 0.86 | TNF (0.80) | TNFTNFSF11TNFRSF1AALDH1A1TSHR | |
| SCHEMBL29477172 | 0.81 | TNF (1.00) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL1270919 | 0.81 | TNF (1.00) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL30645540 | 0.81 | TNF (1.00) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15159836 | 0.71 | TNF (0.81) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15832298 | 0.70 | TNF (0.78) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL20975834 | 0.68 | TNF (0.74) | TNFTNFSF11TNFRSF1AALDH1A1 | |
| SCHEMBL11625434 | 0.67 | MAOB (0.63) | ALDH1A1TSHRRAB9APDE10A | |
| SCHEMBL13296241 | 0.67 | ALDH1A1 (0.66) | ALDH1A1TSHRRAB9APDE10A | |
| Hydrochloric Acid SCHEMBL4944672 | 0.67 | TNFSF11 (0.59) | TNFTNFSF11TNFRSF1AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12171821-B2 | Toxoplasma gondii vaccine | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2024-12-24 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TNF 885/4885TNFSF11 942/4885TNFRSF1A 2247/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TNF 885/4885TNFSF11 942/4885TNFRSF1A 2247/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TNF 885/4885TNFSF11 942/4885TNFRSF1A 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.